Disease · MONDO_0002603

angiomyolipoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. angiomyolipoma. Diseases, record MONDO_0002603. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002603

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: angiomyolipoma; Open Targets
Open Targets ID: MONDO_0002603; Open Targets
Other names: angiomyolipoma (morphologic abnormality); Open Targets
Disease Ontology: DOID:3314; Disease Ontology
MeSH: D018207; MeSH
NCI Thesaurus: C3734; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 2 drugs, from DailyMed; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EVEROLIMUS	CHEMBL1908360	Small molecule	Approval	DailyMed	6	4	4	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Approval	https://conductscience.org/library/genes/2280

Source Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00790400	Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)	Phase 3	118	2012-08-28	Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02539459	Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus	Phase 2	20	2021-02-17	Sporadic Angiomyolipomas (AMLs)	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00457964	RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM	Phase 1/2	36		Tuberous Sclerosis, Lymphangioleiomyomatosis	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00457808	Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM	Phase 2	25		Tuberous Sclerosis, Lymphangioleiomyomatosis	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00792766	Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)	Phase 1/2	20		Tuberous Sclerosis, Angiolipoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32250730	RESULT	1	PubMed
30192751	DERIVED	1	PubMed
30053159	DERIVED	1	PubMed
29023494	DERIVED	1	PubMed
26156073	DERIVED	1	PubMed
18184959	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002603

GET https://conductscience.org/api/diseases/v1/MONDO_0002603/drugs

API reference For AI assistants